Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 257

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 257
---
 on January 30, 2025. In a concurrent private placement, the Company also issued to the investors unregistered warrants (the “January 2025 Warrants”) to purchase up to an aggregate of 408,621shares of common stock at an exercise price of $ 3.855per share. The January 2025 Warrants are exercisable upon issuance, or January 30, 2025, and expire twenty-four months from the date of issuance, or January 30, 2027. As compensation for acting as the placement agent for the January 2025 Offering, the Company paid H.C. Wainwright & Co., LLC a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. The Company also issued to H.C. Wainwright & Co., LLC warrants (the “January 2025 Placement Agent Warrants”) to purchase up to 15,325shares of common stock. The January 2025 Placement Agent Warrants have an exercise price equal to $ 6.382per share and are exercisable upon issuance, or January 30, 2025, and expire twenty-four months from the date of issuance, or January 30, 2027. The January 2025 Offering closed on January 30, 2025, resulting in net proceeds to the Company of approximately $ 804,346, after deducting the placement agent fees and other offering expenses paid by the Company. F-36 February 2025 Offering On February 5, 2025, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering an aggregate of 300,700shares of common stock at a purchase price of $ 3.575per share (the “February 2025 Offering”). The shares were offered pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the SEC on July 18, 2024, as supplemented by a prospectus supplement and accompanying base prospectus filed with the SEC on February 6, 2025. In a concurrent private placement, the Company also issued to the investors unregistered warrants (the “February 2025 Warrants”) to purchase up to an aggregate of 300,700shares of common stock at an exercise price of $ 2.